About
Metandienone, along with other AAS, is a schedule III controlled substance in the United States under the Controlled Substances Act. Metandienone was introduced and formerly sold primarily under the brand name Dianabol. The former synonym should not be confused with methylandrostenolone, which is another name for a different AAS known as metenolone.Metandienone and methyltestosterone are orally active anabolic-androgenic steroids with a 17α-methyl structure that are prohibited in sports but are frequently detected in anti-doping analysis. While the rate of aromatization is reduced relative to that for testosterone or methyltestosterone, the estrogen produced is metabolism-resistant and hence metandienone retains moderate estrogenic activity. Proposed metabolism of methyltestosterone (black, 18 ) and metandienone (red, 12 ) to… Additionally, 3α,5β-tetrahydro-epi-methyltestosterone was identified in the urines of both administrations besides the classical metabolites included in the screening procedures. 17α-hydroxymethyl-17β-methyl-18-nor-5β-androst-13-en-3α-ol and its 5α-analog, were identified following an administration of methyltestosterone.
Chemical structures of phase I metabolites of metandienone reported in the literature. Adverse analytical findings of methyltestosterone… In post-administration urines of metandienone, only the 5β-metabolite was detected. Metandienone is an anabolic steroid indicated for appetite stimulation in patients with anorexia. Metandienone is the generic name of the drug and its INNTooltip International Nonproprietary Name, while methandienone is its BANTooltip British Approved Name and métandiénone is its DCFTooltip Dénomination Commune Française.
As with other 17α-alkylated AAS, metandienone may be hepatotoxic, especially with prolonged use of high doses. As the CIBA product Dianabol, metandienone quickly became the first widely used AAS among professional and amateur athletes, and remains the most common orally active AAS for non-medical use. In case a hereditary predisposition exists, metandienone can cause a possible balding. Methandienone 10mg has a strong effect on the liver that why a long-term therapy is liver-toxic. Methandienone administration in women can cause virilization symptoms.
The co-administration of an antiestrogen such as an aromatase inhibitor like anastrozole or a selective estrogen receptor modulator like tamoxifen can reduce or prevent such estrogenic side effects. Metandienone is a substrate for aromatase and can be metabolized into the estrogen methylestradiol (17α-methylestradiol). As such, 5α-reductase inhibitors like finasteride and dutasteride do not reduce the androgenic effects of metandienone. As with other 17α-alkylated steroids, methandienone poses a risk of hepatotoxicity and use over extended periods of time can result in liver damage without appropriate precautions. Side effects of metandienone include symptoms of masculinization like acne, increased hair growth, voice changes, and increased sexual desire, estrogenic effects like fluid retention and breast enlargement, and liver damage. After the treatment with metandienone, the patients feel a noticeable loss in weight and strength, due to the water excretion from the body, as it was retained in the body during the treatment period.
Androgenic side effects such as oily skin, acne, seborrhea, increased facial/body hair growth, scalp hair loss, and virilization may occur. Metandienone is used for physique- and performance-enhancing purposes by competitive athletes, bodybuilders, and powerlifters. Metandienone was provided in the form of 2.5, 5 and 10 mg oral tablets. Metandienone is readily available without a prescription in certain countries such as Mexico, and is also manufactured in some Asian countries.
Unlike methyltestosterone, owing to the presence of its C1(2) double bond, metandienone does not produce 5α-reduced metabolites. Proposed metabolism of methyltestosterone (black, … Chemical structures of phase I metabolites of methyltestosterone reported in the literature. The candy96.fun drug is an agonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT), and has strong anabolic effects and moderate androgenic effects. Reaction scheme for 17α-hydroxymethyl-17β-methyl-18-nor-5ξ-androst-13-en-3ξ-ol steroids.
It is currently a controlled substance in the United States and United Kingdom and remains popular among bodybuilders. Metandienone was originally developed in 1955 by CIBA and marketed in Germany and the United States.